구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Ixekizumab | Anti-IL17 |
Overview Company | Eli Lilly and Company | Prof. Dr. Stephan Weidinger |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Psoriatic Arthritis | Atopic Dermatitis |
Overview Indication | Psoriasis; Atopic Dermatitis | Atopic Dermatitis; Psoriasis |
Overview Phase | APPROVED | PRECLINICAL |
Overview Status | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Watch |
Overview Approval status | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | Novel approaches, including tolerogenic DC therapy and neuroimmune modulation, hold promise for refining treatment and addres | — |
MoA Mechanism | targets and signaling pathway | targeting the IL-17A pathway |
MoA Biomarker | — | biomarker of immunosuppression |
PK/PD Half-life | 13 h | — |
PK/PD Species | Mouse | Hamster |
PK/PD Animal (cat.) | Mouse | Unknown |
PK/PD Experiment | pharmacokinetic | PD |
Toxicology Species | Mouse | Hamster |
Toxicology Animal (cat.) | Mouse | Unknown |
Toxicology Major finding | Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.. We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We empha… | PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.. Moderate-to-severe plaque psoriasis in the pediatric population represents a complex therapeutic challenge. Although the advent of biologic drugs (anti-TNF, anti-IL17) has revolutionized efficacy standards, there remains an unmet need for oral, safe therapeutic options that do not require regular monitoring. Aprem… |
Clinical Safety signal | Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.. We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We empha… | PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.. Moderate-to-severe plaque psoriasis in the pediatric population represents a complex therapeutic challenge. Although the advent of biologic drugs (anti-TNF, anti-IL17) has revolutionized efficacy standards, there remains an unmet need for oral, safe therapeutic options that do not require regular monitoring. Aprem… |
Clinical Program phase | APPROVED | PRECLINICAL |
Preclinical Animal (cat.) | — | Unknown |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Ixekizumab | Anti-IL17 |
Overview Company | Eli Lilly and Company | Prof. Dr. Stephan Weidinger |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Psoriatic Arthritis | Atopic Dermatitis |
Overview Indication | Psoriasis; Atopic Dermatitis | Atopic Dermatitis; Psoriasis |
Overview Phase | APPROVED | PRECLINICAL |
Overview Status | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Watch |
Overview Approval status | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | Novel approaches, including tolerogenic DC therapy and neuroimmune modulation, hold promise for refining treatment and addres | — |
MoA Mechanism | targets and signaling pathway | targeting the IL-17A pathway |
MoA Biomarker | — | biomarker of immunosuppression |
PK/PD Half-life | 13 h | — |
PK/PD Species | Mouse | Hamster |
PK/PD Animal (cat.) | Mouse | Unknown |
PK/PD Experiment | pharmacokinetic | PD |
Toxicology Species | Mouse | Hamster |
Toxicology Animal (cat.) | Mouse | Unknown |
Toxicology Major finding | Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.. We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We empha… | PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.. Moderate-to-severe plaque psoriasis in the pediatric population represents a complex therapeutic challenge. Although the advent of biologic drugs (anti-TNF, anti-IL17) has revolutionized efficacy standards, there remains an unmet need for oral, safe therapeutic options that do not require regular monitoring. Aprem… |
Clinical Safety signal | Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.. We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We empha… | PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.. Moderate-to-severe plaque psoriasis in the pediatric population represents a complex therapeutic challenge. Although the advent of biologic drugs (anti-TNF, anti-IL17) has revolutionized efficacy standards, there remains an unmet need for oral, safe therapeutic options that do not require regular monitoring. Aprem… |
Clinical Program phase | APPROVED | PRECLINICAL |
Preclinical Animal (cat.) | — | Unknown |
추천 비교
추천 비교